Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
On Dec. 5, Mizuho analyst Vikram Malhotra downgraded the rating for Sabra Health Care REIT from Outperform to Neutral and maintained the price target of $20. On Oct. 31, Sabra Health Care REIT ...
Jan. 16, 2025 — A new tool could make it easier to study scarce plant molecules. Researchers have developed so-called microbial cell factories -- using E. coli and yeast -- to produce a special ...
JMP Securities upgraded Sabra Health Care (SBRA) to Outperform from Market Perform with a $20 price target The firm expects “multiple tailwinds to result in outsized returns” for the stock.